The reason Wall Street might be “sleeping” on B2Gold is not because of weak fundamentals, it’s because the market is over discounting risk while underestimating the impact of Goose and its broader growth pipeline.
Shorting out-of-the-money (OTM) short-dated META puts, buying in-the-money (ITM) long-dated calls, and shorting near-term out-of-the-money calls are three ways to profitably play META.
UnitedHealth Group (NYSE: UNH), the nation's largest health insurer, delivered a disappointing second-quarter earnings report for 2025, sending tremors throughout the financial markets and the broader healthcare sector. The company reported adjusted earnings per share (EPS) of $4.08, significantly missing analyst estimates that ranged from $4.45 to $4.
UnitedHealth Group (NYSE: UNH), a titan in the U.S. healthcare industry, is grappling with a formidable array of financial and operational challenges that are poised to exert immediate and substantial downward pressure on its Q3 2025 Earnings Per Share (EPS) estimates. A confluence of escalating high-acuity care costs, unfavorable
Johnson & Johnson (NYSE: JNJ) is navigating a critical juncture in its protracted legal battle over talc-based baby powder. The healthcare behemoth has announced a tentative $700 million settlement with 43 U.S. states and the District of Columbia to resolve allegations of deceptive marketing practices. Simultaneously, the company has put
UnitedHealth Group (NYSE: UNH), a dominant force in the U.S. healthcare landscape, is currently embroiled in an unprecedented storm of regulatory and legal scrutiny. Federal Justice Department probes targeting its expansive vertical integration and Medicare Advantage billing practices are intensifying, while the company continues to reel from the catastrophic
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving market demands. New drug developments, particularly in sophisticated biologics, groundbreaking gene therapies, and blockbuster obesity treatments, are fundamentally altering therapeutic paradigms. Simultaneously, the pervasive integration of
The global healthcare industry is currently in the midst of a profound metamorphosis, characterized by a rapid influx of technological innovation, significant shifts in policy, and evolving patient expectations. This dynamic environment is not merely reshaping how medical services are delivered, but fundamentally redefining the entire patient experience and the
The global real estate market is bracing for a complex and transformative year in 2025, characterized by a delicate balance between inherent resilience and persistent challenges. As economies recalibrate and central banks navigate evolving interest rate policies, stakeholders are adapting to a nuanced landscape shaped by geopolitical shifts, inflationary pressures,
The global financial landscape is currently undergoing a significant transformation, driven by anticipated and recent interest rate cuts from major central banks worldwide. These pivotal monetary policy shifts are poised to profoundly impact the real estate sector by ushering in an era of cheaper debt and increased liquidity. This environment
Gold’s massive breakout this month has left it pretty stretched technically. Blasting back up into extreme-overbought territory multiplies gold’s odds for an imminent rebalancing selloff.
Procter & Gamble (NYSE: PG) recently disclosed its fiscal third-quarter 2025 results, presenting a nuanced financial picture that has stirred investor sentiment. While the consumer goods titan managed to surpass core earnings per share (EPS) estimates, its net sales declined by 2% to $19.8 billion, falling short of Wall Street's
Procter & Gamble (NYSE: PG), the consumer goods behemoth, reported a modest 1% increase in organic sales for the third quarter of fiscal year 2025. This growth, while seemingly positive, tells a story of increasing reliance on higher prices, as organic volume remained stubbornly flat. The Cincinnati-based company's latest earnings underscore
Costco Wholesale Corporation (NASDAQ: COST) delivered an exceptionally strong performance in the third quarter of fiscal year 2025, significantly outpacing analyst expectations and sending a clear signal of robust consumer demand and effective operational strategies. The warehouse retail giant reported a diluted earnings per share (EPS) of $4.28, comfortably
Costco Wholesale Corporation (NASDAQ: COST) is demonstrating formidable strength in the retail sector, showcasing robust growth in its U.S. comparable sales and a significant surge in e-commerce, underscoring its enduring appeal to consumers. The warehouse giant reported a solid 6.6% increase in U.S. comparable sales and an
The retail sector is currently experiencing a profound transformation, driven by a complex interplay of persistent inflation, evolving consumer priorities, and rapid technological advancements. Consumers, facing economic uncertainties, are adopting more cautious and intentional spending habits, leading to significant immediate implications for major retailers. This shift is compelling companies to
The global energy sector is currently charting a complex course, wrestling with the dual forces of accelerating demand and an imperative shift towards decarbonization. This dynamic environment presents immediate implications for oil prices, demand trends, and the strategic maneuvers of industry titans like ExxonMobil (NYSE: XOM). While traditional fossil fuels
As the global economy navigates a landscape marked by persistent inflation, evolving interest rate policies, and geopolitical uncertainties, major financial institutions like JPMorgan Chase (NYSE: JPM), Visa (NYSE: V), and Mastercard (NYSE: MA) are demonstrating remarkable resilience. Their latest quarterly reports paint a picture of continued strength, driven by robust
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet medical needs. From a groundbreaking FDA approval for bladder cancer to promising Phase 3 results for a next-generation psoriasis treatment and a
